HomeProfessionals Resident Doctor, MSc, Trinh Ngoc Phat
Resident Doctor, MSc,
Trinh Ngoc Phat
Booking
Overview

Dr. Trinh Ngoc Phat is an expert in the field of Dermatology - Internal Aesthetics. Dr. Phat graduated as a Resident Doctor of Dermatology and Master of Medicine from Hanoi Medical University, has many practice certificates in dermatology and cosmetology such as certificates of treatment of general skin diseases, allergic and autoimmune skin diseases, infectious skin diseases, rare and hereditary skin diseases, sexually transmitted diseases, laser certificate, filler injection certificate... Dr. Phat is a member of the Japanese Society for Investigative Dermatology (JSID) and the Vietnam Association of Dermatology. Dr. Phat is constantly learning and cultivating knowledge and skills in dermatology from domestic and foreign experts. Dr. Phat has many studies published domestically and globallt on difficult skin diseases. Dr. Phat also presented in dermatology conferences in Japan, Southeast Asia, Indochina and national dermatology conferences in Vietnam. Dr. Phat has also participated in many multi-center clinical trials in the treatment of difficult skin diseases.

Specialties
Dermatologist
Services
  • General skin diseases
  • Allergic and autoimmune skin diseases
  • Infectious skin diseases
  • Rare and hereditary skin diseases
  • Sexually transmitted diseases
  • Internal cosmetology

2019 - 2022: Resident doctor of Dermatology at National Hospital of Dermatology and Venereology and Hanoi Medical University


2019 - 2022: Master of Medicine at Hanoi Medical University


2022: Certificate: “Laser application in dermatology” - National Hospital of Dermatology and Venereology and “Good Clinical Practice (GCP)” - Ministry of Health


2023: Certificate: “Injectable fillers in skin aesthetics” – National Hospital of Dermatology and Venereology


1/2024 – 2/2024: Dermatology Fellow at Salzburg Open Medical Institute, Austria


2019 – 2022: National Hospital of Dermatology and Venereology


2022 – Now: Vinmec Times City International Hospital


8/2023 – Now: Leader of dermatology block, College of Health Sciences, VinUniversity


Japanese Society for Investigative Dermatology


Vietnam Society of Dermatology & Venereology


  • 2023: Oral presentation at the International Societies for Investigative Dermatology 2023, Tokyo, Japan, 10-13 May 2023
  • 2023: Poster presentation at the European Academy Of Dermatology And Venereology 2023, Berlin, Germany, 11-14 Oct 2023
  • 2023: Oral presentation at the Annual National Conference of Dermatology 2023 in Da Lat, Lam Dong, Vietnam, 23-25 Now 2023
  • 2022: Oral presentation at the Annual National Conference of Dermatology 2022 in Thanh Hoa city, Vietnam, 20-21 May 2022
  • 2022: Oral presentation at the National Conference of Aesthetic Dermatology 2022 in Da Nang, Vietnam. 22-23 July 2022
  • 2022: Oral presentation at the 25th Regional Conference Of Dermatology, Manila, Philippine, 26-28 October 2022
  • 2022: Oral presentation at the Indochina Conference of Dermatology, Phnom Penh, Cambodia, 2-3 December 2022
  • 2023: Oral presentation at the International Societies for Investigative Dermatology 2023, Tokyo, Japan, 10-13 May 2023
  • 2021 - 2022: Study coordinator of “Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE) (CAIN457M2302)”; Sponsor: Novartis Pharmaceuticals; ClinicalTrials.gov Identifier: NCT03713632
  • 2021 - 2022: Study coordinator of “A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe Hidradenitis Suppurativa (SUNNY) (CAIN457M2301E1)”; Sponsor: Novartis Pharmaceuticals; ClinicalTrials.gov Identifier: NCT04179175
  • 2021 - present: Study coordinator of “Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in preventing generalized pustular psoriasis (GPP) flares in patients with history of GPP (Effisayil™ 2) (1368-0027)”; Sponsor: Boehringer Ingelheim; ClinicalTrials.gov Identifier: NCT04399837
  • 2021 - present: Study coordinator of “An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP) (1368-0025)”; Sponsor: Boehringer Ingelheim; ClinicalTrials.gov Identifier: NCT03886246